United Therapeutics Reports Positive Tyvaso Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy UTHR?
Source: seekingalpha
- Clinical Trial Success: United Therapeutics reported that Tyvaso (treprostinil) achieved a primary endpoint in the TETON-1 trial, showing a 130.1 mL increase in absolute forced vital capacity (FVC) compared to placebo, indicating its potential in treating idiopathic pulmonary fibrosis (IPF).
- Risk Reduction: Tyvaso also demonstrated a reduced risk of clinical worsening in TETON-1, excelling in secondary endpoints such as time to first acute exacerbation and changes in predicted FVC, further validating its therapeutic efficacy.
- Significant Treatment Effects: Analyses from TETON-1 and TETON-2 revealed a notable 111.8 mL change in absolute FVC compared to placebo over 52 weeks, enhancing its competitive position in the market.
- Regulatory Submission Plans: The company intends to pursue a priority review of a supplemental New Drug Application (sNDA) for the IPF indication, with a submission targeted by the end of summer, potentially opening new avenues for Tyvaso's market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to fall
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 573.440
Low
423.00
Averages
534.50
High
645.00
Current: 573.440
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Unveils New Data on Pulmonary Hypertension Studies
- Data Presentation: United Therapeutics will present 11 new data sets at the 2026 ISHLT Annual Meeting, focusing on early detection and management of pulmonary hypertension (PH) and interstitial lung disease (ILD), highlighting the critical role of early intervention in improving patient outcomes.
- Significant Treatment Effects: The interim analysis from the ARTISAN study indicates that high-dose treprostinil treatment significantly reduces mean pulmonary artery pressure (mPAP), improves right heart function, and reverses cardiac remodeling in pulmonary arterial hypertension (PAH) patients, potentially reshaping treatment strategies.
- Innovative Technology Utilization: The research includes machine-learning-based prediction techniques for donor lung acceptance, showcasing how artificial intelligence can enhance lung transplant success rates during ex vivo lung perfusion (EVLP), reflecting the company's extensive commitment to scientific innovation.
- Future Outlook: United Therapeutics is dedicated to addressing the shortage of transplantable organs through innovative therapies and breakthroughs in organ manufacturing, demonstrating its mission as a public benefit corporation to provide better treatment options for patients while creating long-term shareholder value.
See More
Morgan Stanley Raises United Therapeutics Price Target to $519
- Price Target Adjustment: Morgan Stanley analyst Terence Flynn raised the price target for United Therapeutics (UTHR) from $471 to $519, reflecting an optimistic outlook on the company's future performance while maintaining an Equal Weight rating, indicating a cautious market sentiment regarding its stock price.
- Model Updates: This adjustment is based on an analysis of IQVIA trends and intra-quarter updates, suggesting that analysts are considering the latest market dynamics and data to more accurately forecast the company's performance in the biopharma sector.
- Market Reaction: With the price target increase, market attention on United Therapeutics may rise, prompting investors to reassess their portfolios in the biopharma space, which could influence stock price volatility.
- Industry Outlook: In the context of United Therapeutics receiving RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA, market expectations for its future products are heightened, potentially driving further growth in the biopharma market.
See More
BKMC Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: BKMC's 52-week low is $86.1665 per share, with a high of $119.18, and the last trade at $113.69 indicates price volatility near the high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable technical insights for investors, aiding in the assessment of price trends and potential buy or sell timing.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets.
See More
FDA Grants Regenerative Medicine Designation to miroliverELAP for Acute Liver Failure
- FDA Designation: The FDA has granted United Therapeutics' miroliverELAP Regenerative Medicine Advanced Therapy designation for treating acute liver failure, highlighting the critical unmet medical need being addressed.
- Technical Overview: Developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics, miroliverELAP utilizes an external blood circuit and a single-use bioengineered liver to provide temporary support for ALF patients, showcasing its innovative approach.
- Clinical Progress: Earlier this year, the company announced positive results from its phase 1 study of miroliverELAP, although full study findings are not expected until the second half of 2026, initial data indicates promising therapeutic potential.
- Market Reaction: UTHR's stock price rose by 1.46% to $573.96 in pre-market trading, reflecting market optimism regarding the therapy's prospects, which may drive future growth for the company.
See More
FDA Grants RMAT Designation to United Therapeutics' miroliverELAP
- Breakthrough Therapy Designation: The FDA has granted United Therapeutics' miroliverELAP® the Regenerative Medicine Advanced Therapy (RMAT) designation, indicating its potential efficacy in treating acute liver failure (ALF) patients, which is expected to expedite its clinical development process.
- Bioengineered Liver Support: Developed by Miromatrix Medical Inc., miroliverELAP utilizes bioengineering techniques, incorporating a decellularized porcine liver scaffold seeded with human endothelial cells to provide temporary liver support, addressing the urgent needs of ALF patients.
- Clinical Trial Progress: Positive results from the phase 1 study of miroliverELAP were announced in January, with full study results expected to be published in the second half of 2026, further validating its effectiveness in treating acute liver failure.
- Organ Alternative Manufacturing Plans: United Therapeutics is also developing mirokidney®, employing the same technology as miroliverELAP, aimed at addressing the ongoing shortage of transplantable organs, showcasing the company's innovative potential in regenerative medicine.
See More
Three High-Potential Stocks to Boost Returns
- United Therapeutics Performance: With a remarkable 16.9% annual revenue growth over the past two years, United Therapeutics has expanded its market share in pulmonary hypertension treatments, while a strong free cash flow margin of 34.2% allows for consistent reinvestment or capital return, enhancing profitability and investment opportunities.
- Coastal Financial Growth: The company has achieved an impressive 40.1% annual net interest income growth over the last five years, indicating significant market share gains, with a strong loan book performance reflected in a best-in-class net interest margin of 7.1%, and an annual EPS growth of 19.6%, far surpassing its peers.
- Chevron's Steady Revenue: Chevron's annual revenue growth of 14.8% over the past five years exceeds the sector average, supported by a massive revenue base of $189 billion that solidifies its market influence, while an 11% free cash flow margin provides flexibility for reinvestment or shareholder returns, further strengthening its market position.
- Market Trend Analysis: These companies exhibit strong revenue growth potential, with five-year returns of 192%, 199%, and 90.7% for United Therapeutics, Coastal Financial, and Chevron respectively, highlighting their competitiveness and future growth prospects in their respective sectors.
See More
United Therapeutics Unveils New Data on Pulmonary Hypertension Studies
- Data Presentation: United Therapeutics will present 11 new data sets at the 2026 ISHLT Annual Meeting, focusing on early detection and management of pulmonary hypertension (PH) and interstitial lung disease (ILD), highlighting the critical role of early intervention in improving patient outcomes.
- Significant Treatment Effects: The interim analysis from the ARTISAN study indicates that high-dose treprostinil treatment significantly reduces mean pulmonary artery pressure (mPAP), improves right heart function, and reverses cardiac remodeling in pulmonary arterial hypertension (PAH) patients, potentially reshaping treatment strategies.
- Innovative Technology Utilization: The research includes machine-learning-based prediction techniques for donor lung acceptance, showcasing how artificial intelligence can enhance lung transplant success rates during ex vivo lung perfusion (EVLP), reflecting the company's extensive commitment to scientific innovation.
- Future Outlook: United Therapeutics is dedicated to addressing the shortage of transplantable organs through innovative therapies and breakthroughs in organ manufacturing, demonstrating its mission as a public benefit corporation to provide better treatment options for patients while creating long-term shareholder value.
See More
Morgan Stanley Raises United Therapeutics Price Target to $519
- Price Target Adjustment: Morgan Stanley analyst Terence Flynn raised the price target for United Therapeutics (UTHR) from $471 to $519, reflecting an optimistic outlook on the company's future performance while maintaining an Equal Weight rating, indicating a cautious market sentiment regarding its stock price.
- Model Updates: This adjustment is based on an analysis of IQVIA trends and intra-quarter updates, suggesting that analysts are considering the latest market dynamics and data to more accurately forecast the company's performance in the biopharma sector.
- Market Reaction: With the price target increase, market attention on United Therapeutics may rise, prompting investors to reassess their portfolios in the biopharma space, which could influence stock price volatility.
- Industry Outlook: In the context of United Therapeutics receiving RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA, market expectations for its future products are heightened, potentially driving further growth in the biopharma market.
See More
BKMC Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: BKMC's 52-week low is $86.1665 per share, with a high of $119.18, and the last trade at $113.69 indicates price volatility near the high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable technical insights for investors, aiding in the assessment of price trends and potential buy or sell timing.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets.
See More
FDA Grants Regenerative Medicine Designation to miroliverELAP for Acute Liver Failure
- FDA Designation: The FDA has granted United Therapeutics' miroliverELAP Regenerative Medicine Advanced Therapy designation for treating acute liver failure, highlighting the critical unmet medical need being addressed.
- Technical Overview: Developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics, miroliverELAP utilizes an external blood circuit and a single-use bioengineered liver to provide temporary support for ALF patients, showcasing its innovative approach.
- Clinical Progress: Earlier this year, the company announced positive results from its phase 1 study of miroliverELAP, although full study findings are not expected until the second half of 2026, initial data indicates promising therapeutic potential.
- Market Reaction: UTHR's stock price rose by 1.46% to $573.96 in pre-market trading, reflecting market optimism regarding the therapy's prospects, which may drive future growth for the company.
See More
FDA Grants RMAT Designation to United Therapeutics' miroliverELAP
- Breakthrough Therapy Designation: The FDA has granted United Therapeutics' miroliverELAP® the Regenerative Medicine Advanced Therapy (RMAT) designation, indicating its potential efficacy in treating acute liver failure (ALF) patients, which is expected to expedite its clinical development process.
- Bioengineered Liver Support: Developed by Miromatrix Medical Inc., miroliverELAP utilizes bioengineering techniques, incorporating a decellularized porcine liver scaffold seeded with human endothelial cells to provide temporary liver support, addressing the urgent needs of ALF patients.
- Clinical Trial Progress: Positive results from the phase 1 study of miroliverELAP were announced in January, with full study results expected to be published in the second half of 2026, further validating its effectiveness in treating acute liver failure.
- Organ Alternative Manufacturing Plans: United Therapeutics is also developing mirokidney®, employing the same technology as miroliverELAP, aimed at addressing the ongoing shortage of transplantable organs, showcasing the company's innovative potential in regenerative medicine.
See More
Three High-Potential Stocks to Boost Returns
- United Therapeutics Performance: With a remarkable 16.9% annual revenue growth over the past two years, United Therapeutics has expanded its market share in pulmonary hypertension treatments, while a strong free cash flow margin of 34.2% allows for consistent reinvestment or capital return, enhancing profitability and investment opportunities.
- Coastal Financial Growth: The company has achieved an impressive 40.1% annual net interest income growth over the last five years, indicating significant market share gains, with a strong loan book performance reflected in a best-in-class net interest margin of 7.1%, and an annual EPS growth of 19.6%, far surpassing its peers.
- Chevron's Steady Revenue: Chevron's annual revenue growth of 14.8% over the past five years exceeds the sector average, supported by a massive revenue base of $189 billion that solidifies its market influence, while an 11% free cash flow margin provides flexibility for reinvestment or shareholder returns, further strengthening its market position.
- Market Trend Analysis: These companies exhibit strong revenue growth potential, with five-year returns of 192%, 199%, and 90.7% for United Therapeutics, Coastal Financial, and Chevron respectively, highlighting their competitiveness and future growth prospects in their respective sectors.
See More
